trial · primary record
Zanzalintinib
Neoadjuvant Treatment
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2030-10-01 |
| Primary endpoint | Safety and adverse events |
| Registry ID | NCT06959511 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:45.214Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06959511
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Zanzalintinib · compound